PLUS THERAPEUTICS, Inc. (PSTV): Price and Financial Metrics


PLUS THERAPEUTICS, Inc. (PSTV): $0.44

0.01 (+2.84%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PSTV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PSTV Stock Price Chart Interactive Chart >

Price chart for PSTV

PSTV Price/Volume Stats

Current price $0.44 52-week high $1.20
Prev. close $0.43 52-week low $0.29
Day low $0.42 Volume 207,200
Day high $0.45 Avg. volume 402,917
50-day MA $0.39 Dividend yield N/A
200-day MA $0.53 Market Cap 14.86M

PLUS THERAPEUTICS, Inc. (PSTV) Company Bio


PLUS THERAPEUTICS, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops, and commercializes specialty novel therapeutics for the treatment of cancer and other life-threatening diseases. PLUS THERAPEUTICS operates in the States of Texas and California.


PSTV Latest News Stream


Event/Time News Detail
Loading, please wait...

PSTV Latest Social Stream


Loading social stream, please wait...

View Full PSTV Social Stream

Latest PSTV News From Around the Web

Below are the latest news stories about PLUS THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTV as an investment opportunity.

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trial AUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium (186Re) obisbemeda f

Yahoo | January 18, 2023

Why Plus Therapeutics Inc. (NASDAQ: PSTV) Stock Shouldn’t Be Ignored In 2023

In the last trading session, 1.23 million shares of the Plus Therapeutics Inc. (NASDAQ:PSTV) were traded, and its beta was 0.30. Most recently the company’s share price was $0.48, and it changed around $0.09 or 23.89% from the last close, which brings the market valuation of the company to $13.01M. PSTV currently trades at a … Why Plus Therapeutics Inc. (NASDAQ: PSTV) Stock Shouldn’t Be Ignored In 2023 Read More »

Marketing Sentinel | January 17, 2023

Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot Precision

Plus Therapeutics, Inc. (Nasdaq: PSTV) specializes in targeted radiation treatments Rather than traditional radiation beams, Plus uses needle-sized applicators into brain fluid Focused on brain cancer which is difficult to […]

Yahoo | January 5, 2023

Plus Therapeutics Inc. (NASDAQ:PSTV) Drops -3.46%, But Further Rally Could Be Imminent

In last trading session, Plus Therapeutics Inc. (NASDAQ:PSTV) saw 0.4 million shares changing hands with its beta currently measuring 0.36. Company’s recent per share price level of $0.30 trading at -$0.01 or -3.46% at ring of the bell on the day assigns it a market valuation of $9.99M. That closing price of PSTV’s stock is … Plus Therapeutics Inc. (NASDAQ:PSTV) Drops -3.46%, But Further Rally Could Be Imminent Read More »

Marketing Sentinel | December 17, 2022

Was anything negative for Plus Therapeutics Inc. (PSTV) stock last session?

In Monday’s session, Plus Therapeutics Inc. (NASDAQ:PSTV) marked $0.35 per share, down from $0.39 in the previous session. While Plus Therapeutics Inc. has underperformed by -9.95%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PSTV fell by -71.99%, with highs and lows ranging from $2.16 to […]

US Post News | December 13, 2022

Read More 'PSTV' Stories Here

PSTV Price Returns

1-mo 33.33%
3-mo -10.20%
6-mo -8.56%
1-year -55.40%
3-year -80.62%
5-year -99.82%
YTD 38.80%
2022 -69.81%
2021 -48.02%
2020 -15.83%
2019 -83.45%
2018 -90.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7287 seconds.